Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Chronic Lymphocytic Leukemia

Breast Cancer

Gastrointestinal Cancer

Colorectal Cancer

Ovarian Cancer

Prostate Cancer

Precision Medicine in Oncology^®

Neoadjuvant HER2+

More >>

Chronic Lymphocytic Leukemia

Zanubrutinib Faces Off Against Ibrutinib in CLL Trial

Armed with the knowledge that inhibition of the Bruton tyrosine kinase is an effective approach in B-cell malignancies, investigators will explore the efficacy of the second-generation BTK inhibitor, zanubrutinib, in 2 leukemia and lymphoma subtypes.
Read More >>

Woyach Highlights Progress and Next Steps in CLL Paradigm

Building on BTK Inhibition in CLL

Sharman Showcases Frontline Acalabrutinib Activity in CLL

ASH 2019: Acalabrutinib Benefit in CLL Sustained With Long-Term Follow-Up

ASH 2019: Liso-Cel Continues to Show Promise in Relapsed/Refractory CLL/SLL

View More Stories >>

View Conference Coverage

2019 San Antonio Breast Cancer Symposium

2019 ASH Annual Meeting

2019 International Congress of the Society for Melanoma Research

2019 State of the Science Summit on Genitourinary Cancers in Nashville

2019 State of the Science Summit on Hematologic Malignancies in Chicago

Dr. Fakhri on Tumor Lysis Syndrome Associated With Venetoclax/Obinutuzumab in CLL

Dr. Woyach on Ongoing Research With BTK Inhibitors in CLL

Dr. Fakhri on Selecting the Optimal Treatment in CLL

Dr. Leslie on Real-World Outcomes of Patients With CLL Treated With Acalabrutinib

Dr. Woyach on Frontline Treatment Options in CLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

Risk Assessment in Newly Diagnosed CLL

CLL: Practical Advice on Selecting and Managing Therapy

Acalabrutinib's Role in Treating Chronic Lymphocytic Leukemia

Venetoclax + Obinutuzumab: Impact on CLL Management

Frontline Therapy in CLL: Combination Strategies and MRD

Stratifying Patients With CLL to Frontline Therapy

Ibrutinib's Role as Frontline Therapy in CLL

OncLive houses thousands of videos that provide updates and information.
See more Videos

BTK Inhibitors in Chronic Lymphocytic Leukemia

Genomic Profiling in Chronic Lymphocytic Leukemia

Venetoclax-Based Regimens as First-Line Therapy in CLL

$Relapsed/Refractory CLL: Evaluating Other Novel Agents$

$Novel Approaches to Treating Relapsed/Refractory CLL$

$Continuing Therapy in Relapsed/Refractory CLL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Other Promising Strategies in CLL

This expert panel discussion led by William Wierda, MD, focuses on promising strategies available for the treatment of chronic lymphocytic leukemia. Dr. Wierda is joined in this discussion by Steven Coutre, MD; Matthew S. Davids, MD, MMSc; Nicole Lamanna, MD; and Shuo Ma, MD, PhD.

View Now

The Use of Novel PI3K Inhibitors in CLL

In this segment William Wierda, MD, PhD, leads a panel discussion regarding the use of novel PI3K inhibitors in chronic lymphocytic leukemia.

View Now

Featured Video

Dr. Esteva on the Future of Biosimilars in Breast Cancer

Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now

FDA Approvals in Urothelial Cancer and GIST, Promising Data in Urothelial Carcinoma, and More